

FIG. 1a



FIG. 1b



FIG. 1c


Oligo size versus IC50 (HSV-1)
y = -0.7432x + 17.322
R² = 0.9864
IC50 (uM)
6.0
5.0
4.0
3.0
2.0
1.0
0.0
15
17
19
21
23
oligo size (bases)

FIG. 2

FIG. 3a



FIG. 3b



FIG. 3c



FIG. 3d



FIG. 3e



FIG. 3f



FIG. 3g




Oligo size versus IC50 (HSV-1)
IC50 acyclovir
log IC50 (uM)
0.6
0.4
0.2
0.0
-0.2
-0.4
-0.6
-0.8
-1.0
-1.2
-1.4
15
20
25
30
35
40
45
y = -0.077x + 1.8591
R² = 0.9956
oligo size (bases)

FIG. 4



FIG. 5a



FIG. 5b



FIG. 5c



FIG. 5d



FIG. 5e



FIG. 5f



FIG. 5g



FIG. 5h



FIG. 5i



FIG. 6


Oligo size vs IC50 (HSV-1)
log IC50 (uM)
3
2
1
0
-1
-2
-3
0
20
40
60
80
100
120
140
oligo size (bases)

FIG. 7



FIG. 8a



FIG. 8b



FIG. 8c



FIG. 8d



FIG. 8e



FIG. 8f



FIG. 8g



FIG. 8h



FIG. 8i



FIG. 9


DNA composition vs IC50 (KOS)
random sequence (PS)
HSV sequence (PS)
randomers (PS) from figure 5
IC50 (uM)
3
2.5
2
1.5
1
0.5
0
0
10
20
30
40
50
oligo length (bp)

FIG. 10



FIG. 11a



FIG. 11b



FIG. 11c



FIG. 11d



FIG. 12a



FIG. 12b



FIG. 12c


Oligo size versus IC50 (HSV-2)
y = -0.1596x + 3.9764
R² = 0.8343
IC50 (uM)
2.0
1.5
1.0
0.5
0.0
15
17
19
21
23
oligo size (bases)

FIG. 13

FIG. 14a



FIG. 14b



FIG. 14c



FIG. 14d



FIG. 14e



FIG. 14f



FIG. 14g




Oligo size versus IC50 (HSV-2)
1.0
0.5
0.0
-0.5
-1.0
-1.5
-2.0
-2.5
log IC50 (uM)
IC50
15
20
25
30
35
40
45
oligo size (bases)

FIG. 15



FIG. 16a



FIG. 16b



FIG. 16c



FIG. 17a



FIG. 17b



FIG. 17c



FIG. 17d



FIG. 17e



FIG. 17f



FIG. 17g



FIG. 17h



FIG. 17i


Oligo size vs IC50 (CMV)
log IC50 (uM)
0.8
0.6
0.4
0.2
0
-0.2
-0.4
-0.6
-0.8
-1
0
20
40
60
80
100
oligo size (base pairs)

FIG. 18



FIG. 19a



FIG. 19b



FIG. 19c



FIG. 19d


Oligo size vs IC50 (HIV)
log IC50 (uM)
0
-0.5
-1
-1.5
-2
-2.5
0
10
20
30
40
50
oligo size (bases)

FIG. 20



FIG. 21a



FIG. 21b

Lopinavir (Kaletra™)



FIG. 21c

Saquinavir (Fortovase™)



FIG. 21d



FIG. 21e



FIG. 21f



FIG. 21g



FIG. 21h

Drug	IC50 (uM)
REP 2003	4.01
REP 2004	0.065
REP 2006	0.014
REP 2007	0.015
Amprenavir	0.016
Indinavir	0.006
Lopinavir	0.004
Saquinavir	0.003

FIG. 22a



FIG. 22b



FIG. 23a



FIG. 23b



FIG. 23c



FIG. 23d



FIG. 23e



FIG. 23f



FIG. 23g



FIG. 23h

Drug	IC50 (uM)		Fold change in IC50
	HIV-1 NL4-3	HIV-1 MRDC4	
REP 2003	4.01	3.69	0.92
REP 2004	0.065	0.046	0.71
REP 2006	0.014	0.014	1.00
REP 2007	0.015	0.013	0.87
Amprenavir	0.017	0.065	3.82
Indinavir	0.006	0.08	13.33
Lopinavir	0.004	0.096	24.00
Saquinavir	0.003	0.006	2.00

FIG. 24



FIG. 25a



FIG. 25b



FIG. 25c



FIG. 25d



FIG. 25e



FIG. 25f



FIG. 25g



FIG. 25h


Oligo size vs IC50 (RSV)
Ribavirin IC50
1.5
1
0.5
0
-0.5
-1
-1.5
-2
log IC50 (uM)
0
20
40
60
80
100
oligo size (bases)

FIG. 26



FIG. 27a



FIG. 27b



FIG. 28a



FIG. 28b



FIG. 28d



FIG. 28c



FIG. 28e



FIG. 29a



FIG. 29b



FIG. 29c



FIG. 30a



FIG. 30b



FIG. 30c


p24 and gp41 binding to HIV lysate
mP
200
180
160
140
120
100
80
60
40
20
0
1ug
HIV-1 p24
2ug
HIV-1 p24
1ug
HIV-1 gp41
2ug
HIV-1 gp41
2004FL-F

FIG. 31



FIG. 32a



FIG. 32b


Single and double stranded PS-ODNs can bind both HSV-1 and HIV-1 lysates
mP
300
250
200
150
100
50
0
REP 2017U ds
REP 2017U ds +HIV
REP 2017U ds +HSV
REP 2017U ss
REP 2017U ss + HIV
REP 2017U ss + HSV
REP 2017 ds
REP 2017 ds + HIV
REP 2017 ds + HSV
REP 2017 ss
Rep2017 ss + HIV
Rep2017 ss + HSV

FIG. 33


Cellular Uptake of REP 2004-FL
RFU (480/530)
45000
40000
35000
30000
25000
20000
15000
10000
5000
0
no tx
oligofectamine
lipofectamine
polyfect
delivery

FIG. 34



FIG. 35a



FIG. 35b



FIG. 35c


REPLICOR compounds versus Vaccinia
% survival
160
140
120
100
80
60
40
20
0
no virus
no drug
REP 2004
REP 2006
REP 2007
Cidofovir
vaccinia (1X10^7.9 TCID50/ml)

FIG. 36



FIG. 37a



FIG. 37b